Clinical trial NCT02106182: Efficacy and Safety of Silodosin on Nocturia for Patients With Benign Prostatic Hyperplasia
Official title: A Multi-center, Prospective, Open-label, Single-arm, 12-weeks, Phase IV Trial to Evaluate the Efficacy and Safety of Silodosin on Nocturia for Patients With Benign Prostatic Hyperplasia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Nocturia
Benign Prostatic Hyperplasia
Keywords: Benign prostatic hyperplasia
Nocturia
Silodosin
Thrupas
Lead sponsor: JW Pharmaceutical
Sponsor class: INDUSTRY
First posted: 2014-04-08
Enrollment: 135
Sex: MALE
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The objective of this study is to determine safety and efficacy of silodosin, which is a treatment for benign prostatic hyperplasia with high selectivity to α1A-receptor, on patients with benign prostatic hyperplasia accompanied by nocturia.

Detailed description: This study is designed as a multi-center, prospective, open-label and single-arm study. Subjects who are willing to provide written informed consent will be enrolled after screening for eligibility criteria. The subjects will be administered with investigational product for 12 weeks and visit as outpatients for evaluation of safety and efficacy at baseline (visit 2) and 4 weeks (visit 3) and 12 weeks (visit 4) after baseline.

Eligibility criteria: Inclusion Criteria:

* Males of at least 50 years of age, with current diagnosis of benign prostatic hyperplasia
* Symptoms of nocturia evidenced by ≥2 episodes per night in average according to 3-day voiding diary
* More than total of 8 points on IPSS and 3 points on QoL
* Able to provide written informed consent and to comply with all study procedures

Exclusion Criteria:

* PSA level \> 10 ng/㎖ (except patients who had 4 ng/㎖ \< PSA level ≤ 10 ng/㎖ 6 months prior to screening and identified as negative from biopsy)
* Symptoms of postural hypotension
* Severe renal disorders or creatinine clearance ≥ 2.0 mg/dL
* Severe hepatic disorders or AST or ALT ≥ 3 x upper limit of normal (ULN)
* Severe cardiac disorders or development or diagnosis of vascular disorder (unstable angina, myocardial infarction, cerebral infarction, cerebral hemorrhage, coronary artery bypass graft, etc) 6 months prior to enrollment
* Any disorder of the gastrointestinal system which could result in altered digestion or absorption, history of gastrointestinal tract surgery except ecphyadectomy
* Patients with bladder cancer, cystolith or urethral stricture
* Patients with neurogenic bladder
* History of acute urinary retention
* Indwelling catheter or self intermittent catheterization
* Patients with pyuria 1 month prior to screening
* History of prostatic cancer
* History of prostatic surgery
* Patients with uncontrolled chronic disease
* Alcoholism or sustained drug dependent abuse 1 year prior to screening
* Hypersensitivity to α1A-receptor blockers
* Administration of following drugs within according periods prior to screening - 2 weeks: Antimuscarinic agents (Tolterodine, Trospium, Solifenacin, Fesoterodine, Propiverine, Oxybutynin, Flavoxate, etc), Anticholinesterase agents (Neostigmine methylsulfate, etc), Cholinergic agonists (Bethanechol Cl, etc), Benign prostatic hyperplasia agents (Tamsulosin HCl, Prazosin HCl, Terazosin HCl, Doxazosin mesylate, Silodosin, Naftopidil, etc), Tricyclic antidepressants (Amitriptyline, Clomipramine, Dosulepin, Doxepin, Imipramine, Quinupramine, etc), 6 months: 5-α-Reductase Inhibitors (Finasteride, Dutasteride)
* Presence of a condition or abnormality that in the opinion of the investigator would compromise the safety of the patient or the quality of the data

Primary outcomes:
measure: Incidence of nocturia
timeFrame: 12 weeks
Secondary outcomes:
measure: Mean change in International Prostate Symptom Score(IPSS) from baseline
timeFrame: 12 weeks
measure: Mean change in Quality of Life(QoL) scores from baseline
timeFrame: 12 weeks
measure: Mean change in Overactive Bladder Symptom Score(OABSS) from baseline
timeFrame: 12 weeks
measure: Mean change in International Consultation on Incontinence modular Questionnaire-Nocturia(ICIQ-N) from baseline
timeFrame: 12 weeks
measure: Mean change in Questions 3, 5 and 6 (voiding symptoms) of IPSS from baseline
timeFrame: 12 weeks
measure: Mean change in Question 1 (postvoiding symptoms) of IPSS from baseline
timeFrame: 12 weeks
measure: Mean change in Questions 2, 4 and 7 (storage symptoms) from baseline
timeFrame: 12 weeks
measure: Ratio of subjects with ≥ 25% decrease in incidence of nocturia
timeFrame: 12 weeks
measure: Ratio of subjects with ≥ 25% decrease in IPSS
timeFrame: 12 weeks
Other outcomes:
Locations:
city: Bucheon
country: Korea, Republic of
facility: Bucheon St.Mary's Hospital
state: Gyeonggi-do
city: Suwon
country: Korea, Republic of
facility: Ajou University Hospital
state: Gyeonggi-do
city: Busan
country: Korea, Republic of
facility: Pusan Natonal University Hospital
city: Daejeon
country: Korea, Republic of
facility: Eulji University Hospital
city: Seoul
country: Korea, Republic of
facility: Hanyang University Hospital
city: Seoul
country: Korea, Republic of
facility: Soon Chun Hyang University Hospital
Study officials:
References: